ESC 24: Hot Line & Late-breaking Science Video Collection

Published: 15 August 2024

  • Views:

    Views Icon 2985

  • Likes:

    Heart Icon 7
Average (ratings)
No ratings
Your rating

Overview

What's hot at the ESC Congress 2024?

Stay ahead of the curve with our faculty-led coverage of the European Society of Cardiology Congress in London. From groundbreaking trials to expert insights, we've got you covered.

  • Watch our View From the Thoraxcenter series for practice-focused reviews of the most anticipated trials from interventional experts, Prof Nicolas Van Mieghem and Dr Joost Daemen. 
  • For a deeper dive into key hot line clinical trial data and its applicability, host, Dr Harriette Van Spall meets with principal investigators in her Late-Breaker Discussion series.
  • View a condensed summary of the crucial takeaways from each day in our Wrap-Up series led by Dr Mirvat Alasnag.
  • Our short, bite-sized Expert Interviews with select faculty will focus on data, take-home messages for practice and the future of their field.

Get ready for a deep dive into the latest cardiology research. Our coverage of the ESC Congress is coming soon.

More from this programme

Part 1

View From the Thoraxcenter: What's Hot at ESC 24?

2 sessions
ESC Congress 2024 Hot Line Wrap Up Watch now
ESC Congress 2024 Hot Line Preview Watch now

Part 2

Daily Wrap Ups with Dr Alasnag and Dr Al-Shaibi

4 sessions
ESC Day 1 Wrap Up: New Guidelines, HELIOS-B, ABYSS & STOP-or-NOT Watch now
ESC Day 2 Wrap-Up: NOTION-3, RESHAPE-HF2, TRI.Fr & More Watch now
Day 3 Wrap-Up with Dr Alasnag and Dr Al-Shaibi Watch now
Day 4 Wrap-Up: OCCUPI, REC-CAGEFREE I, AEGIS-II & More Watch now

Part 3

Hot-line Discussions with Dr Harriette Van Spall

5 sessions
AβYSS: Beta Blocker Interruption After Uncomplicated MI Watch now
RHEIA: TAVR vs SAVR in Women with Severe AS Watch now
OCEANIC-AF: Asundexian Vs Apixaban in Atrial Fibrillation Watch now
SWEDEGRAFT: No-touch Vein Graft in CABG Watch now
FINEARTS-HF: Finerenone HFmEF & HFpEF Watch now

Part 4

Expert Interviews

13 sessions
Bridging the Gap in Heart Failure Guideline Implementation from a Specialist Nurse Perspective Watch now
MATTERHORN: M-TEER vs Surgery in Heart Failure Watch now
MRAs in Heart Failure Watch now
FINE-HEART: Finerenone in HF & CKD Watch now
STEEER-AF: Stroke Prevention & Rhythm Control Therapy Watch now
NOTION-3: FFR Guided PCI in TAVI Watch now
EPIC-CAD: Edoxaban vs Dual Antiplatelet Therapy in AF & CAD Watch now
SENIOR RITA: Invasive Vs Conservative Strategy for Older Patients with MI Watch now
EARTH-STEMI: Complete Vs Culprit-Only Revascularization in Older Patients Watch now
SCOFF: Fasting vs. Non-Fasting: Impact on Cardiac Catheterization Outcomes Watch now
GUARD-AF: Atrial Fibrillation Screening to Reduce Stroke in Elderly Individuals Watch now
SHAM-PVI: Sham Study of Pulmonary Vein Isolation in Symptomatic Atrial Fibrillation Watch now
POPular PAUSE TAVI: Continuation or interruption of OAC During TAVI Watch now

Part 5

Highlights

2 sessions
3 Trials That Will Change My Practice With Dr Muthiah Vaduganathan Watch now
3 Trials That Will Change My Practice With Dr Michelle Kittleson Watch now

Part 6

Guidelines

2 sessions
New Guidelines for the Management of Atrial Fibrillation Watch now
New Guidelines for the Management of Aortic Diseases Watch now

About the episode

ESC Congress 2024 — Edoxaban monotherapy significantly improves outcomes in high-risk patients with CAD and atrial fibrillation.

Investigators, Dr Gi-Byoung Nam (Ulsan University Hospital, Ulsan, SK) and Dr Min Soo Cho (Asan Medical Center, Seoul, SK) join us to discuss the key findings from the EPIC-CAD trial (NCT03718559).

This Korean multi-centre, open-labelled, randomised controlled study investigated the effectiveness and safety of edoxaban monotherapy compared to edoxaban combined with an antiplatelet agent in 1040 patients with stable coronary artery disease (CAD) with a stenosis of at least 50% on medical management or post-revascularisation (at least 12 months after acute coronary syndrome or 6 months after stable CAD), and who also have a high risk of atrial fibrillation (CHA2DS2-VASc score ≥2). The primary outcome measure was a composite of clinical events at one year.

Findings showed that edoxaban monotherapy significantly reduced the risk of a net composite outcome of death by any cause, stroke, systemic embolism, myocardial infarction unplanned revascularisation and major or clinically relevant non-major bleeding at one year after revascularisation by 56% compared with dual antithrombotic therapy. 

Interview Questions: 

  1. What is the importance of this trial?
  2. What was the study design, eligibility criteria and outcome measures?
  3. What were the baseline characteristics of randomised patients?
  4. What are the key findings? (Safety and efficacy)
  5. Were there any significant differences in treatment effect between pre-specified sub-groups of patients?
  6. What conclusions can be made for practice?
  7. What are the next steps?

Recorded on-site at ESC Congress 2024, London.

Editors: Jordan Rance and Mirjam Boros.
Videographers: Mike Knight, Dan Brent, Oliver Miles, Tom Green, David-Ben-Harosh.

Support: This is an independent interview produced by Radcliffe Cardiology.

Faculty Biographies

Gi-Byoung Nam

View full profile

Min Soo Cho

View full profile

Comments

You must be to comment. If you are not registered, you can register here.